Professor Sharon Lewin is an infectious diseases physician and basic scientist, who is internationally renowned for her research into all aspects of HIV disease and specifically in strategies to achieve an HIV cure. Professor Lewin is the inaugural Director of the Doherty Institute and the Cumming Global Centre for Pandemic Therapeutics, a new centre at the Doherty Institute established by a philanthropic gift of $250 million from Canadian philanthropist Geoff Cumming and $75 million from the Victorian government. She is also a Melbourne Laureate Professor of Medicine at The University of Melbourne and the immediate Past President of the International AIDS Society (IAS) (2022 – 2024), the largest professional society representing people working in HIV medicine and has over 14,000 members. She is an Advisory Board member for the National Foundation for Australia-China Relations (NFACR), a Board Director for Doherty Clinical Trials Ltd and President of the Scientific Advisory Board of the ANRS/MIE, the largest funder of all infectious diseases research in France.
She received her medical degree (1986) and PhD (1997) from Monash University and post doctoral training at the Rockefeller University, New York (1997-1999). She heads a laboratory of 25 scientists and clinicians working on basic and translational research and early phase clinical trials aimed at finding a cure for HIV, understanding how HIV interacts with hepatitis B and novel antiviral strategies for SARS-CoV2. Her laboratory is funded by the NHMRC, the Medical Research Future Fund, the National Institutes of Health, the American Foundation for AIDS Research, mRNA Victoria and multiple commercial partnerships and philanthropic grants. She is also the Chief Investigator of The Australian Partnership for Preparedness Research on Infectious Diseases Emergencies (APPRISE) funded by the Federal Government, that aims to bring together Australia’s leading experts in clinical, laboratory and public health research to address key challenges in managing COVID19, including long COVID and antiviral utilisation in both indigenous and non-indigenous Australians.
Professor Paul Gorry joined the Doherty Institute in 2023 as Deputy Director. Prior to this appointment Paul held several leadership positions at RMIT over a nine-year period, including Director of Higher Degrees by Research, Deputy Pro-Vice Chancellor (Research and Innovation), and Dean of Science and Health (Research and Innovation). Prior to his positions at RMIT, Paul was Senior Principal Research Fellow at the Burnet Institute, Deputy Head of the Institute’s Centre for Biomedical Research, and Principal of the cross-cutting theme of Immunity, Vaccines and Immunisation. His research expertise is broadly in the areas of virology and immunology, which developed from postdoctoral positions at Harvard Medical School and the Dana Farber Cancer Institute in Boston. Despite taking a step back from research in 2015 to pursue leadership roles at RMIT, he remains research active and is widely recognised as an expert on HIV pathogenesis and the early steps of viral entry.
Kirsten Noakes is the Chief Operating Officer, leading the Institute’s Operations, Finance, People & Culture, Facility Management and Events. With a track record of driving organisational improvements and building high-performing teams, Kirsten brings extensive experience to the role. She joins the Institute from The Royal Children’s Hospital (RCH), where she has held several senior management and executive positions since 2017, most recently serving as Chief Operating Officer. During her tenure at RCH, she led transformative organisation-wide projects to improve patient care and service delivery, including the hospital’s COVID-19 response.
A values-based leader, Kirsten is committed to excellence through a culture of curiosity, collaboration, respect and inclusivity – qualities that will be key to driving the Institute’s next phase of growth and impact.
Sarah Yallop is the Director of Corporate Affairs & Strategy, leading the Institute’s Government Relations, Marketing and Communications, Advancement and Strategic Planning. Sarah has qualifications in applied science and policy studies and has extensive experience working in the health system, including prevention and public health program management and government policy roles. Sarah has worked at the NSW and Victorian Departments of Health in a broad range of policy and strategy roles including health reform, NDIS, aged care and primary care. Before joining the Doherty Institute in mid-2022, she held the position of Director of COVID-19 Pathology Strategy & Innovation at the Victorian Department of Health.
Professor Andrew Brooks is an immunologist interested in immune recognition strategies, in particular how immune cells discriminate healthy cells from those infected with viruses or tumours. Before establishing a laboratory in the Department of Microbiology and Immunology, Andrew completed a PhD in immunology at Flinders University in South Australia and post-doctoral training at the National Institutes of Health, USA. It was here Andrew developed an interest in the receptors used by lymphocytes called natural killer cells that allow them to target tumours or virus-infected cells. Since returning to the University of Melbourne, Andrew’s research has continued to focus largely on receptors that regulate lymphocyte activation.
Professor Trubiano is an Infectious Diseases Physician, Director of Infectious Diseases at Austin Health and Head of the Department of Infectious Diseases in the Melbourne Medical School. He is an NHMRC Emerging Leadership Fellow at the University of Melbourne, Department of Infectious Diseases. He is the laboratory head for the Centre for Antibiotic Allergy and Research (Austin Health) and his research explores health services programs for antibiotic allergy and novel diagnostics and pharmacogenomic predictors for severe T-cell mediated drug reactions.
Professor Ben Howden is Director of the Microbiological Diagnostic Unit Public Health Laboratory (MDU PHL), Medical Director of Doherty Applied Microbial Genomics and Head of the Howden Research Group. Ben is responsible for the provision of public health laboratory services, the translation of microbial genomics into clinical practice, and research investigating antimicrobial resistance and bacterial pathogenesis, evolution and host-pathogen interactions. Ben has been the recipient of many research awards including the American Society for Microbiology ICAAC Young Investigator Award (2011), the Australian Society for Microbiology Frank Fenner Award (2014) and the Australasian Society for Infectious Diseases Frank Fenner Award (2015). Ben is currently Deputy Chair of the Public Health Laboratory Network Australia, President of the Australian Society for Antimicrobials, and an Executive Member of the Australian Group on Antibiotic Resistance.
Dr Chuan Kok Lim is a Medical Virologist and Acting Director of the Victorian Infectious Diseases Reference Laboratory (VIDRL). He is also a co-lead for the Viral Infectious Diseases Theme at the Doherty Institute. He plays a role in leading the public health laboratory response to disease outbreak investigation and surveillance. Chuan is an Honorary Fellow of the Department of Infectious Diseases and a member of the Viral Infectious Diseases cross-cutting discipline at the Doherty Institute. He is a member of the Williamson Group and a clinician-scientist with special research focus on translational virology for emerging pathogens, in particular viral functional genomics and novel diagnostics.
Professor James McCarthy is Director of the Victorian Infectious Diseases Service at the Royal Melbourne Hospital, and Professor of Medicine at the Doherty Institute. His research has focussed on the diagnosis and treatment of parasitic diseases, with a major recent focus on the development and application of clinical trial systems that entail deliberate infection of human volunteers with malaria and other pathogenic organisms. This has enabled study of the host-pathogen interaction, development of diagnostic biomarkers and the evaluation of investigational drugs and vaccines.
Professor Kirsty Buising is an infectious diseases physician who is Deputy Director of the National Centre for Antimicrobial Stewardship and chief investigator for the National Health and Medical Research Council (NHMRC) funded Centre for Research Excellence in Antimicrobial Stewardship. Kirsty also holds an appointment as a clinician at VIDS and co-leads the antimicrobial resistance theme at the Doherty institute. She serves on advisory groups at state, national and international levels in the areas of antimicrobial stewardship, guideline development and healthcare associated infection.
Professor Jodie McVernon is a physician with subspecialty qualifications in public health and vaccinology. She has extensive expertise in clinical vaccine trials, epidemiologic studies and mathematical modelling of infectious diseases, gained at the University of Oxford, Health Protection Agency London and The University of Melbourne. Her work focuses on the application of a range of cross-disciplinary methodological approaches including mathematical and computational models, to synthesise insights from basic biology, epidemiological data and sociological research. These models advance understanding of the observed epidemiology of infectious diseases and inform understanding of optimal interventions for disease control.
Dr Shivani Pasricha is a laboratory head in the Department of Infectious Diseases at the Doherty Institute, spearheading rapid point-of-care diagnostics for infectious diseases with advanced technologies like CRISPR. She holds honorary positions at Victorian Infectious Diseases Reference Laboratory and the Walter and Eliza Hall Institute, and sits on the executive committee for the ARC funded ITRP antimicrobial resistance hub, world-first partnership between industry, researchers and end users to transform AMR and stewardship. Her team utilizes molecular and genomic approaches to enhance detection, prevention, and surveillance of infectious diseases, addressing critical clinical challenges.
